125
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Potential benefit of entacapone for cocaine addiction: two case reports

&
Pages 594-597 | Received 07 Sep 2015, Accepted 17 Oct 2015, Published online: 06 Apr 2016

References

  • Boettiger, C. A., Mitchell, J. M., Tavares, V. C., Robertson, M., Joslyn, G., D'Esposito, M., & Fields, H. L. (2007). Immediate reward bias in humans: fronto-parietal networks and a role for the catechol-Omethyltransferase 158Val/Valgenotype. The Journal of Neuroscience, 27, 14383–14391.
  • COMT. (2013, December 9). Inhibitors up adherence to opioid maintenance treatment. Medscape.
  • Egan, M. F., Goldberg, T. E., Kolachana, B. S., Callicott, J. H., Mazzanti, C. M., Straub, R. E., Goldman, D., & Weinberger, D. R. (2001). Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proceedings of the National Academy of Sciences of the United States of America, 98(12), 6917–6922.
  • Fellers, J. C. (2014). Pilot study of entacapone for methamphetamine abuse. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: https://clinicaltrials.gov/ct2/show/NCT02058966 [last accessed 1 Sep 2015]. NLM Identifier: NCT02058966.
  • Herman, A. I., Jatlow, P. I., Gelernter, J., Listman, J. B., Sofuoglu, M. (2013). COMT Val158Met modulates subjective responses to intravenous nicotine and cognitive performance in abstinent smokers. Pharmacogenomics Journal, 13(6).
  • Jentsch, J. D., & Taylor, J. R. (1999). Impulsivity resulting from frontostriatal dysfunction in drug abuse: implications for the control of behavior by reward-related stimuli. Psychopharmacology (Berl), 146, 373–390.
  • Kayser, A. S., Allen, D. C., Navarro-Cebrian, A., Mitchell, J. M., & Fields, H. L. (2012). Dopamine, corticostriatal connectivity, and inter temporal choice. The Journal of Neuroscience, 32(27), 9402–9409.
  • Olanow, W., & Watkins, P. B. (2007). Tolcapone: an efficacy and safety review. Clinical Neuropharmacology, 30(5), 287–294.
  • Parkinson's Drug Shows Promise in Alcohol Dependence. (2011, December 15). Medscape.
  • Shafa, R. (2013, December). COMT inhibitors up adherence to opioid maintenance treatment. Poster session presented at the American Academy of Addiction Psychiatry (AAAP) 24th Annual Meeting & Symposium, Scottsdale, Arizona, USA.
  • Shafa, R., & Abdolmaleky, H. M. (2009). COMT-inhibitors may be a promising tool in treatment of marijuana addiction. The American Journal of Addictions, 18(s), 322.
  • Tammimaki, A. E., & Mannisto, P. T. (2010). Are genetic variants of COMT associated with addiction? Pharmacogenet Genomics, 20(12), 717–741.
  • Weinshilboum, R. M., Otterness, D. M., & Szumlanski, C. L. (1999). Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase. Annual Review of Pharmacology and Toxicology, 39, 19–52.
  • Winstanley, C. A., Olausson, P., Taylor, J. R., & Jentsch, J. D. (2010). Insight into de relationship between impulsivity and substance abuse from studies using animal models. Alcoholism: Clinical and Experimental Research, 34(8), 1–13.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.